Profile: Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

114.00DKK
10:59am EDT
Price Change (% chg)

kr.-0.50 (-0.44%)
Prev Close
kr.114.50
Open
kr.114.00
Day's High
kr.116.00
Day's Low
kr.113.00
Volume
32,516
Avg. Vol
77,843
52-wk High
kr.136.00
52-wk Low
kr.59.50

Search Stocks
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines within biodefence, cancer and infectious diseases therapeutic areas. The Company operates within two segments: Cancer Vaccines and Infectious Disease. The Cancer Vaccines’ pipeline is focused on therapeutic vaccines and includes two projects in prostate cancer, PROSTVAC and MVA-BN PRO; two projects in breast cancer, CV-301 and MVA-BN HER2; one project in lung cancer, CV-301 lung, and one project in ovarian cancer, CV-301 ovarian. The Infectious Disease’s pipeline is focused on prophylactic vaccines and includes a smallpox vaccine candidate; an anthrax vaccine candidate, MVA-BN Anthrax, and a RSV vaccine candidate, MVA-BN RSV. Bavarian Nordic A/S has research centers in Mountain View in the United States and Martinsried in Germany, and manufacturing facilities in Kvistgaard, Denmark, and Berlin, Germany.

Company Address

Bavarian Nordic A/S

Hejreskovvej 10A
KVISTGAARD     3490

Search Stocks